Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068914 | 0.78 | CYP1A2 (0.34) | TAAR1 | |
| SCHEMBL17654251 | 0.77 | — | — | |
| SCHEMBL16446433 | 0.76 | TAAR1 (0.30) | TAAR1 | |
| SCHEMBL3528117 | 0.76 | TAAR1 (0.30) | TAAR1 | |
| SCHEMBL3513783 | 0.75 | — | — | |
| SCHEMBL3087157 | 0.74 | NOTUM (0.33) | — | |
| SCHEMBL20526130 | 0.74 | TAAR1 (0.33) | TAAR1 | |
| SCHEMBL2068190 | 0.74 | GLA (0.34) | — | |
| SCHEMBL3430713 | 0.74 | NFE2L2 (0.35) | — | |
| SCHEMBL2066759 | 0.74 | CACNA1C (0.34) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229917-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | claimed |
| US-20230271951-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2023-08-31 | — | — | US | disclosed |
| WO-2023152042-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2023-08-17 | — | — | WO | disclosed |
| EP-4132650-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-02-15 | — | — | EP | disclosed |
| EP-4017591-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-29 | — | — | EP | disclosed |
| EP-3774741-B1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-08 | — | — | EP | disclosed |
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | UCB Biopharma SRL (BE) | 2021-04-01 | — | — | US | disclosed |
| WO-2021032687-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | WO | disclosed |
| EP-3774741-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-17 | — | — | EP | disclosed |
| WO-2012151440-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2417123-A2 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118063-A2 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-1606277-B8 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | disclosed |
| EP-1606277-B1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-7153874-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1606277-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20040229917-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | disclosed |
| WO-2004080998-A1 | IMIDAZOL-4-YL-ETHYNYL-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271951-A1 | DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS | IL17A, IL2, IL23R | TAAR1 4098/4885HSD11B1 377/4885 |
| US-20040229917-A1 | Imidazole derivatives | GRIK4, GRIA4, GRIK5 | TAAR1 183/4885HSD11B1 4383/4885 |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | G6PD, DPYD, DHODH | TAAR1 3536/4885HSD11B1 2490/4885 |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | TAAR1 4306/4885HSD11B1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.